Investigators found that patients failing front-line venetoclax + hypomethylating agents had high-risk biology, dismal overall survival despite salvage therapy, and new putative mechanisms of resistance.
[Haematologica]
Maiti, A., Rausch, C. R., Cortes, J. E., Pemmaraju, N., Daver, N. G., Ravandi, F., Garcia-Manero, G., Borthakur, G., Naqvi, K., Ohanian, M., Short, N. J., Alvarado, Y., Kadia, T. M., Takahashi, K., Yilmaz, M., Jain, N., Kornblau, S., Bravo, G. M., Sasaki, K., … Konopleva, M. Y. (2021). Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica, 106(3), 894–898. https://doi.org/10.3324/haematol.2020.252569 Cite
0